ARVN.US Arvinas Inc

Healthcare Pharmaceuticals USA Stocks
6.82 USD
Close of Nov 13, 2026
6.33 14.51
Market cap
USD 447M
P/E
-
P/B
0.87x
ROE
15.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARVN.US undervalued?

Graham number

The Graham number of Arvinas Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arvinas Inc fundamental analysis

No fundamental analysis for Arvinas Inc yet.

Arvinas Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase …

Full company profile